ISSN Print 2713-0894    ISSN Online 2713-0908
BIOMEDICAL JOURNAL OF ERMC EASTERN EUROPEAN

New articles

The rapid aging of the population and development of early diagnostic technologies for neurodegenerative diseases pose new ethical challenges. By 2026, genetic and biomarker testing methods for predisposition to Alzheimer’s disease (AD) and Parkinson’s disease (PD) had become clinically available. However, their adoption has outpaced the development of ethical, legal, and social mechanisms for their responsible use. This article analyzes two sets of ethical issues related to the early diagnosis of AD and PD in the context of an “aging society.” The first group is related to presymptomatic testing in the absence of effective prevention methods. This includes the ethical dilemma of “to know or not to know,” the right to information and the right “not to know,” psychological risks (82% of physicians note a high level of stress in tested patients), social stigmatization (70% of physicians report it) and discrimination, as well as legal gaps in the protection of biomarker data. The second group of dilemmas stems from the ontological uncertainty of mild cognitive impairment (MCI), a condition situated on the borderline between physiological aging and pathology. The risks of overdiagnosis and unwarranted intervention, the problem of “psychological continuity” of personality and challenges of respecting autonomy in patients with cognitive impairments (the inability of roughly 20% of individuals with MCI to provide informed consent) are explored. The following ethical guidelines are proposed: improving informed consent, establishing a system for long-term psychosocial support, expanding legal protections for biomarker data, and reducing stigmatization within the framework of the active longevity concept.
VIEWS 17
This study examines how stigmas among specialists in tuberculosis care (phthisiologists) make the profession less popular and result in emotional burnout. The professional stigma is based on several factors such as the fear of contamination in an institution with inadequate infectious safety standards; transfer of social stigmas about tuberculosis (viewing it strictly as a disease of poverty and social dysfunction) onto healthcare professionals; an underestimation of the complexity of phthisiology as a contemporary, high-tech medical field; and a deficit in organizational protection for healthcare personnel. It is essential to differentiate between reasonable caution and stigma. Thus, a rational response to the professional risk is represented by infectious control rather than by social distancing. Reasonable response to the risk is to make infectious control perfect and protect the rights of the personnel instead of alienating and devaluing the profession. A combination of measures can make the problem less acute. The combination can include information and educational programs, safe labor conditions, confidentiality warranties, protection against workplace violence, a fair distribution of workload, and the formal recognition of phthisiology as a comprehensive, high-tech clinical discipline This approach enhances not only the well-being of staff and staff retention in tuberculosis services, but also strengthens trust of patients, improves the quality of care, and facilitates the achievement of broader healthcare objectives in global tuberculosis control.
VIEWS 286

Popular articles

This review examines the ethical and legal implications of creating pharmacogenetic passports during the preconception (prior to conception) and prenatal (intrauterine) periods. The work is based on a methodological differentiation between the stages of genetic testing.. Preconception screening aims to assess carrier status in prospective parents and ensure their reproductive freedom, while prenatal testing provides fetus-related data, raising bioethical issues regarding the protection of interests and self-determination of the future child. The technologies of non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and prospects for intrauterine pharmacotherapy in severe congenital abnormalities are discussed. Special attention is given to ethical conflicts such as a conflict between the right to health and the right not to know, limits of parental proxy, and risk of genetic stigmatization. Normative approaches are suggested to address the identified ethical tensions (minimum intervention, clinical benefit, and deferred choice). The analysis of the Russian legislation and international instruments (Oviedo Convention, the GINA Act, the GDPR) yields recommendations for the healthcare system and legal regulation.
VIEWS 2364